ICER Report Suggests Lower Price for Lecanemab Than Aduhelm
December 22, 2022
The Institute for Clinical and Economic Review (ICER) has issued a report evaluating the value and cost-effectiveness of two amyloid-targeted therapeutics for Alzheimer’s disease. Biogen and Eisai’s lecanemab was deemed by the agency to be cost effective if priced between $9,000 and $21,000, whereas Eli Lilly’s donanemab was valued between $14,500 and $46,900, although evidence was limited regarding the latter.
According to , “In comparing lecanemab and Aduhelm, Biogen and Eisai’s controversial approved Alzheimer’s drug, ICER noted that its optimistic threshold then was $11,000 to $25,000. (In its final report, it suggested an un-optimistic range of $2,950 to $8,360 for Aduhelm.) Notably, both are lower than Aduhelm’s current list price of $28,200, which is now about half its original list price of $56,000.”
To read more, click here.
(Source: Endpoints News, December 22nd, 2022)
